ArticleInternational journal of oncology2020

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.

Chi Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.